"Fatty Liver" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Descriptor ID |
D005234
|
| MeSH Number(s) |
C06.552.241
|
| Concept/Terms |
Steatohepatitis- Steatohepatitis
- Steatohepatitides
- Steatosis of Liver
- Visceral Steatosis
- Steatoses, Visceral
- Steatosis, Visceral
- Visceral Steatoses
- Liver Steatosis
- Liver Steatoses
- Steatoses, Liver
- Steatosis, Liver
|
Below are MeSH descriptors whose meaning is more general than "Fatty Liver".
Below are MeSH descriptors whose meaning is more specific than "Fatty Liver".
This graph shows the total number of publications written about "Fatty Liver" by people in this website by year, and whether "Fatty Liver" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 2 | 3 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 1 | 3 |
| 2009 | 5 | 0 | 5 |
| 2010 | 2 | 0 | 2 |
| 2011 | 3 | 5 | 8 |
| 2012 | 4 | 3 | 7 |
| 2013 | 3 | 2 | 5 |
| 2014 | 2 | 1 | 3 |
| 2015 | 3 | 2 | 5 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 2 | 0 | 2 |
| 2023 | 5 | 2 | 7 |
| 2024 | 5 | 2 | 7 |
| 2025 | 11 | 0 | 11 |
| 2026 | 7 | 1 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fatty Liver" by people in Profiles.
-
ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol. 2026 Nov; 11(11):984-996.
-
Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics. Aliment Pharmacol Ther. 2026 Nov; 64(9):1184-1196.
-
Vertical Sleeve Gastrectomy Versus Comprehensive Lifestyle Intervention for Adolescents With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Controlled Cohort Study. Aliment Pharmacol Ther. 2026 Sep; 64(6):758-769.
-
Recruitment of Minority Patients in Metabolic Dysfunction-Associated Steatotic Liver Disease Clinical Trials. Dig Dis Sci. 2026 Sep; 71(9):4235-4241.
-
Clinical Outcomes and Non-Invasive Testing in Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Review. Liver Int. 2026 05; 46(5):e70608.
-
Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis. Med. 2026 May 08; 7(5):101077.
-
Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management. Nat Rev Gastroenterol Hepatol. 2026 Jun; 23(6):460-474.
-
Histology of amiodarone-induced liver injury revisited: A retrospective morphologic analysis. Ann Diagn Pathol. 2026 Jun; 82:152623.
-
Resolution of Biochemical and Histologic Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adolescents with Severe Obesity after Metabolic Bariatric Surgery. J Pediatr. 2026 04; 291:114944.
-
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study. Lancet Gastroenterol Hepatol. 2026 Mar; 11(3):232-242.